Canada markets closed

CRMD Jun 2024 5.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.4000+0.0200 (+5.26%)
As of 03:44PM EDT. Market open.
Full screen
Previous Close0.3800
Open0.3500
Bid0.3000
Ask0.4000
Strike5.00
Expire Date2024-06-21
Day's Range0.3500 - 0.4000
Contract RangeN/A
Volume38
Open Interest518
  • Insider Monkey

    CorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript

    CorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript May 11, 2024 CorMedix Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the CorMedix First Quarter 2024 Earnings Conference Call [Operator Instructions]. Today’s conference call is […]

  • GlobeNewswire

    CorMedix Inc. to Participate in Two Upcoming Investor Conferences

    BERKELEY HEIGHTS, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 13 – 14, 2024 and the 2024 RBC Capital Markets Global Healthcare Conference being held in New York o

  • GlobeNewswire

    CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

    Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business. Recent Corporate Highlights: On April 2, 2024, CMS published its HCPCS coding decision for DefenCa